Tuesday, May 23, 2017 11:48:15 PM
The thing about this company is that they managed to have a revenue stream without Myocell in the US. I am guessing that they will show a profit of .02/share next q without RMAT approval based on the last Q as well as the role that GACP will play on the income statement. That would bring the stock price up substantially.
That all assumes the worst case scenario. Chances are really good that they get RMAT approval and we see a few bucks at worst and $18 at best. Then shortly after, we get a buyout offer.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM